The DOI matches its Crossref record; 612 of the 626 references it cites were found in a registry or an index.
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Abstract
Immunology-based therapies are emerging as an effective cancer treatment, using the body's immune system to target tumors. Immune checkpoints, which regulate immune responses to prevent tissue damage and autoimmunity, are often exploited by cancer cells to avoid destruction. The discovery of checkpoint proteins like PD-1/PD-L1 and CTLA-4 was pivotal in developing cancer immunotherapy. Immune checkpoint inhibitors (ICIs) have shown great success, with FDA-approved drugs like PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab, Tremelimumab), alongside LAG-3 inhibitor Relatlimab. Research continues on new checkpoints like TIM-3, VISTA, B7-H3, BTLA, and TIGIT. Biomarkers like PDL-1 expression, tumor mutation burden, interferon-γ presence, microbiome composition, and extracellular matrix characteristics play a crucial role in predicting responses to immunotherapy with checkpoint inhibitors. Despite their effectiveness, not all patients experience the same level of benefit, and organ-specific immune-related adverse events (irAEs) such as rash or itching, colitis, diarrhea, hyperthyroidism, and hypothyroidism may occur. Given the rapid advancements in this field and the variability in patient outcomes, there is an urgent need for a comprehensive review that consolidates the latest findings on immune checkpoint inhibitors, covering their clinical status, biomarkers, resistance mechanisms, strategies to overcome resistance, and associated adverse effects. This review aims to fill this gap by providing an analysis of the current clinical status of ICIs, emerging biomarkers, mechanisms of resistance, strategies to enhance therapeutic efficacy, and assessment of adverse effects. This review is crucial to furthering our understanding of ICIs and optimizing their application in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–600 of 612
Khan, S. A., Pruitt, S. L., Xuan, L., & Gerber, D. E. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2238 · Cited by 161
Immune regulation and control of regulatory T cells by OX40 and 4-1BB
So, T., Lee, S., & Croft, M. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.04.003 · Cited by 156
Cheung, T. C., Oborne, L. M., Steinberg, M. W., Macauley, M. G., Fukuyama, S., Sanjo, H., D'Souza, C., Norris, P. S., Pfeffer, K., MURPHY, K. M. M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902490 · Cited by 156
Song, Y., Gao, Q., Zhang, H., Fan, L., Zhou, J., Zou, D., Li, W., Yang, H., Liu, T., Wang, Q., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0545-2 · Cited by 156
VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity
ElTanbouly, M. A., Croteau, W., Noelle, R. J., & Lines, J. L. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101308 · Cited by 155
Celis-Gutierrez, J., Blattmann, P., Zhai, Y., Jarmuzynski, N., Ruminski, K., Grégoire, C., Ounoughene, Y., Fiore, F., Aebersold, R., Roncagalli, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.041 · Cited by 154
The intimate relationship between gut microbiota and cancer immunotherapy
Elkrief, A., Derosa, L., Zitvogel, L., Kroemer, G., & Routy, B. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1527167 · Cited by 153
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions
Xu, F., Sunderland, A., Zhou, Y., Schulick, R. D., Edil, B. H., & Zhu, Y. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2031-x · Cited by 152
Mao, Y., Eißler, N., Blanc, K. L., Johnsen, J. I., Kogner, P., & Kiessling, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1912 · Cited by 151
Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy
Sun, J., Qiao, L., Sanmamed, M. F., & Wang, J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2925 · Cited by 151
Lipson, E. J., Tawbi, H. A.-H., Schadendorf, D., Ascierto, P. A., Matamala, L., Gutiérrez, E. C., Rutkowski, P., Gogas, H., Lao, C. D., Janoski de Menezes, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9503 · Cited by 150
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
Spain, L. A., Higgins, R. M., Gopalakrishnan, K., Turajlic, S., Gore, M. E., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw130 · Cited by 150
Ascierto, P. A., Bono, P., Bhatia, S., Melero, I., Nyakas, M., Svane, I. M., Larkin, J., Gomez‐Roca, C., Schadendorf, D., Dummer, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.011 · Cited by 150
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Gray, J. E., Saltos, A. N., Tanvetyanon, T., Haura, E. B., Creelan, B., Antonia, S. J., Shafique, M. R., Zheng, H., Dai, W., Saller, J. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1305 · Cited by 150
Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer
Kazemi, M. H., Mohseni, S. R., Hojjat‐Farsangi, M., Anvari, E., Ghalamfarsa, G., Mohammadi, H., & Jadidi‐Niaragh, F. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25873 · Cited by 149
Immunotherapeutic effects of intratumoral nanoplexed poly I:C
Aznar, M. A., Planelles, L., Pérez‐Olivares, M., Molina, C., Garasa, S., Etxeberría, I., Pérez, G., Rodríguez, I., Bolaños, E., Lopez-Casas, P. P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0568-2 · Cited by 149
Naluai, Å. T., Nilsson, S., Samuelsson, L., Gudjónsdóttir, A. H., Ascher, H., Ek, J., Hallberg, B., KRISTIANSSON, B., Martinsson, T., Nerman, O., et al. (2000) · Tissue Antigens · doi:10.1034/j.1399-0039.2000.560407.x · Cited by 147
Kalbasi, A. K., Tariveranmoshabad, M., Hakimi, K. N., Kremer, S. V., Campbell, K. M., Funes, J. M., Vega-Crespo, A., Parisi, G., Champhekar, A. S., Nguyen, C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0152 · Cited by 144
Xu, W., Hiếu, T., Malarkannan, S., & Wang, L. L. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.148 · Cited by 143
Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0810 · Cited by 142
Kondo, Y., Ohno, T., Nishii, N., Harada, K., Yagita∥, H., & Azuma, M. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.04.005 · Cited by 142
Jalil, A. R., Andrechak, J. C., & Discher, D. E. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa006 · Cited by 142
PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
Xu, X., Hou, B., Fulzele, A., Masubuchi, T., Zhao, Y., Wu, Z., Hu, Y., Jiang, Y., Ma, Y., Wang, H., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201905085 · Cited by 142
Wang, P. L., O'Farrell, S., Clayberger, C., & Krensky, A. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.8.2600 · Cited by 139
Qi, Z., Xu, Z., Zhang, L., Zou, Y., Li, J., Yan, W., Li, C., Liu, N., & Wu, H. (2022) · Nature Communications · doi:10.1038/s41467-021-27833-0 · Cited by 137
VISTA: Coming of age as a multi-lineage immune checkpoint
ElTanbouly, M. A., Schaafsma, E., Noelle, R. J., & Lines, J. L. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13415 · Cited by 135
Signal regulatory protein alpha (SIRPα)/CD47 interaction and function
Barclay, A. N. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.008 · Cited by 134
Angata, T., & der Linden, E. B.-V. (2002) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00316-1 · Cited by 133
Zhou, C., Huang, D., Fan, Y., Yu, X., Liu, Y., Shu, Y., Ma, Z., Wang, Z., Cheng, Y., Wang, J., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.217 · Cited by 133
Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M.-J., Yuno, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3305 · Cited by 133
Huard, B., Prigent, P., Pagès, F., Bruniquel, D., & Triebel, F. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260533 · Cited by 132
New roles for TIM family members in immune regulation
Kuchroo, V. K., Dardalhon, V., Xiao, S., & Anderson, A. C. (2008) · Nature reviews. Immunology · doi:10.1038/nri2366 · Cited by 131
Naing, A., Wong, D. J. L., Infante, J. R., Korn, W. M., Aljumaily, R. M., Papadopoulos, K. P., Autio, K. A., Pant, S., Bauer, T. M., Drakaki, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30514-5 · Cited by 131
Kameda, Y., Takahata, M., Komatsu, M., Mikuni, S., Hatakeyama, S., Shimizu, T., Angata, T., Kinjo, M., Minami, A., & Iwasaki, N. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1989 · Cited by 128
Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection
Alhamad, T., Venkatachalam, K., Linette, G. P., & Brennan, D. C. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13711 · Cited by 127
Induction of the CTLA-4 Gene in Human Lymphocytes Is Dependent on NFAT Binding the Proximal Promoter
Gibson, H. M., Hedgcock, C. J., Aufiero, B. M., Wilson, A. J., Hafner, M. S., Tsokos, G. C., & Wong, H. K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3831 · Cited by 126
G protein-coupled receptors--recent advances.
Latek, D., Modzelewska, A., Trzaskowski, B., Palczewski, K., & Filipek, S. (2012) · Acta Biochimica Polonica · doi:10.18388/abp.2012_2086 · Cited by 126
The NKG2A immune checkpoint — a new direction in cancer immunotherapy
Creelan, B., & Antonia, S. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0182-8 · Cited by 125
Alvey, C. M., Spinler, K. R., Irianto, J., Pfeifer, C. R., Hayes, B. H., Xia, Y., Cho, S., Dingal, P. C. D. P., Hsu, J., Smith, L., et al. (2017) · Current Biology · doi:10.1016/j.cub.2017.06.005 · Cited by 123
TIM-3 Regulates Distinct Functions in Macrophages
Ocaña‐Guzmán, R., Torre-Bouscoulet, L. I., & Sada‐Ovalle, I. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00229 · Cited by 122
Clinical Significance of the HLA-E and CD94/NKG2 Interaction
Iwaszko, M., & Bogunia‐Kubik, K. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0137-y · Cited by 122
Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
Yin, S., Chen, Z., Chen, D., & Yan, D. (2023) · Theranostics · doi:10.7150/thno.80091 · Cited by 121
Immune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Structural basis of G protein-coupled receptor function
Schöneberg, T., Schultz, G., & Gudermann, T. W. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00017-9 · Cited by 117
Saleh, R., Toor, S. M., Khalaf, S., & Elkord, E. (2019) · Vaccines · doi:10.3390/vaccines7040149 · Cited by 117
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
Wang, J., Yuan, R., Song, W., Sun, J., Liu, D., & Li, Z. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0403-5 · Cited by 116
Coming of Age: CD96 Emerges as Modulator of Immune Responses
Georgiev, H., Ravens, I., Papadogianni, G., & Bernhardt, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01072 · Cited by 115
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
Smith, S. M., WACHTER, K., Burris, H. A., Schilsky, R. L., George, D. J., Peterson, D. E., Johnson, M. L., Markham, M. J., Mileham, K. F., Beg, M. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03420 · Cited by 115
Shi, G., Yang, Q., Zhang, Y., Jiang, Q., Lin, Y., Yang, S., Wang, H., Cheng, L., Zhang, X., Li, Y., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.010 · Cited by 113
Clinical landscape of LAG-3-targeted therapy
Chocarro, L., Blanco, E., Arasanz, H., Fernández, L., Bocanegra, A., Echaide, M., Garnica, M., Ramos, P., Fernández-Hinojal, G., Vera, R., et al. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100079 · Cited by 113
Clinical advances in targeting epigenetics for cancer therapy
Feng, S., & Carvalho, D. D. D. (2021) · FEBS Journal · doi:10.1111/febs.15750 · Cited by 112
Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers
Oshima, T., Sato, S., Kato, J., Ito, Y., Watanabe, T., Tsuji, I., Hori, A., Kurokawa, T., & Kokubo, T. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-60 · Cited by 109
Josefsson, S. E., Huse, K., Kolstad, A., Beiske, K., Pende, D., Steen, C. B., Inderberg, E. M., Lingjærde, O. C., Østenstad, B., Smeland, E. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2337 · Cited by 108
Lu, C., Liu, Z., Klement, J. D., Yang, D., Merting, A. D., Poschel, D. B., Albers, T., Waller, J. L., Shi, H., & Liu, K. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002624 · Cited by 108
Lee, D. J., Lee, H. J., Farmer, J. R., & Reynolds, K. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01530-2 · Cited by 108
Ishida‐Kitagawa, N., Tanaka, K., Bao, X., Kimura, T., Miura, T., Kitaoka, Y., Hayashi, K., Sato, M., Maruoka, M., Ogawa, T., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.324194 · Cited by 106
Deuss, F. A., Gully, B. S., Rossjohn, J., & Berry, R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.786483 · Cited by 104
Li, R., Salehi‐Rad, R., Crosson, W. P., Momcilovic, M., Lim, R. J., Ong, S. L., Huang, Z. L., Zhang, T.-H., Abascal, J. W., Dumitras, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3564 · Cited by 104
The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy
Paucek, R. D., Baltimore, D., & Li, G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.002 · Cited by 104
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
Herz, S., Höfer, T., Papapanagiotou, M., Leyh, J., Meyenburg, S., Schadendorf, D., Ugurel, S., Roesch, A., Livingstone, E., Schilling, B., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.026 · Cited by 102
Sonpavde, G., Necchi, A., Gupta, S., Steinberg, G. D., Gschwend, J. E., Heijden, M. S. V. D., Garzon, N., Ibrahim, M. F. K., Raybold, B., Liaw, D., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0611 · Cited by 101
The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1
Seth, S., Maier, M. K., Qiu, Q., Ravens, I., Kremmer, E., Förster, R., & Bernhardt, G. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.102 · Cited by 99
Hamid, M. A., Wang, R., Yao, X., Fan, P., Li, X., Chang, X.-M., Feng, Y., Jones, S., Maldonado‐Pérez, D., Waugh, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0885 · Cited by 98
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
Qu, T., Li, B., & Wang, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00373-5 · Cited by 98
mTOR Signaling in T Cell Immunity and Autoimmunity
Liu, Y., Zhang, D., & Liu, X. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2014.933957 · Cited by 97
Godal, R., Bachanová, V., Gleason, M., McCullar, V., Yun, G. H., Cooley, S., Verneris, M. R., McGlave, P. B., & Miller, J. S. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.01.019 · Cited by 97
Xu, Z., & Jin, B. (2010) · Cellular and Molecular Immunology · doi:10.1038/cmi.2009.108 · Cited by 96
Powles, T. B., Vogelzang, N. J., Fine, G. D., Eder, J. P., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Teng, S.-L. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5011 · Cited by 96
BTLA: a new inhibitory receptor with a B7-like ligand
Carreno, B. M., & Collins, M. A. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.08.005 · Cited by 95
Hiruma, Y., Hirai, T., & Tsuda, E. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.05.015 · Cited by 95
Regulation of T cell responses by the receptor molecule Tim-3
Gorman, J. V., & Colgan, J. D. (2014) · Immunologic Research · doi:10.1007/s12026-014-8524-1 · Cited by 94
Tomkowicz, B. E., Walsh, E. S., Cotty, A., Verona, R. I., Chi-Sabins, N., Kaplan, F. M., Santulli-Marotto, S., Chin, C., Mooney, J. M., Lingham, R. B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140694 · Cited by 94
Márquez‐Rodas, I., Longo, F., Rodriguez-Ruiz, M. E., Calles, A., Ponce, S., Jové, M., Rubio‐Viqueira, B., Perez‐Gracia, J. L., Gómez‐Rueda, A., López‐Tarruella, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0391 · Cited by 93
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
Sauer, N. J., Szlasa, W., Jonderko, L., Oślizło, M., Kunachowicz, D., Kulbacka, J., & Karłowicz-Bodalska, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179958 · Cited by 93
Guo, Z., Yuan, Y., Chen, C., Lin, J., Ma, Q., Liu, G., Gao, Y. L., Huang, Y., Chen, L., Chen, L., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00279-3 · Cited by 92
Borggrewe, M., Grit, C., Den Dunnen, W. F. A., Burm, S. M., Bajramovic, J. J., Noelle, R. J., Eggen, B. J. L., & Laman, J. D. (2018) · Glia · doi:10.1002/glia.23517 · Cited by 91
Ju, F., Luo, Y., Lin, C., Jia, X., Xu, Z., Tian, R., Lin, Y., Zhao, M., Chang, Y., Huang, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004762 · Cited by 90
Harrington, K. J., Ferris, R. L., Gillison, M. L., Tahara, M., Argiris, A., Fayette, J., Schenker, M., Bratland, Å., Walker, J. W. T., Grell, P., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0147 · Cited by 90
Deciphering the role of CD47 in cancer immunotherapy
Liu, Y., Weng, L., Wang, Y., Zhang, J., Wu, Q., Zhao, P., Shi, Y., Wang, P., & Fang, L. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.10.009 · Cited by 90
Guo, L., Wei, R., Lin, Y., & Kwok, H. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01508 · Cited by 89
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 89
Foster, C. C., Couey, M., Kochanny, S. E., Khattri, A., Acharya, R. K., Tan, Y. C., Brisson, R. J., Leidner, R. S., & Seiwert, T. Y. (2021) · Cancer · doi:10.1002/cncr.33780 · Cited by 89
B7-H3 Inhibitors in Oncology Clinical Trials: A Review
Feustel, K., Martin, J., & Falchook, G. S. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-23-18 · Cited by 88
Liu, X., Guo, C., Tou, F., Wen, X., Kuang, Y., Zhu, Q., & Hu, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32744 · Cited by 87
The CD47 “don't eat me signal” is highly expressed in human ovarian cancer
Brightwell, R. M., Grzankowski, K. S., Lele, S., Eng, K. H., Arshad, M., Chen, H., & Odunsi, K. O. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.08.325 · Cited by 86
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 86
Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA
Gavrieli, M., & Murphy, K. M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.036 · Cited by 85
G Protein–Coupled Receptor Connectivity to NF-κB in Inflammation and Cancer
Fraser, C. C. (2008) · International Reviews of Immunology · doi:10.1080/08830180802262765 · Cited by 85
Mérida, I., Andrada, E., Gharbi, S., & Ávila‐Flores, A. (2015) · Science Signaling · doi:10.1126/scisignal.aaa0974 · Cited by 85
Genomic structure, chromosome location, and alternative splicing of the human NKG2A gene
Plougastel-Douglas, B., Jones, T. A., & Trowsdale, J. (1996) · Immunogenetics · doi:10.1007/bf02602558 · Cited by 82
Molecular characterization of recombinant human adenosine receptors
Robeva, A., Woodard, R. L., Jin, X., Gao, Z., Bhattacharya, S., Taylor, H. E., Rosin, D. L., & Linden, J. M. (1996) · Drug Development Research · doi:10.1002/(sici)1098-2299(199611/12)39:3/4<243::aid-ddr3>3.0.co;2-r · Cited by 79
Flies, D. B., Higuchi, T., & Chen, L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402648 · Cited by 78
Hosseinkhani, N., Derakhshani, A., Shadbad, M. A., Argentiero, A., Racanelli, V., Kazemi, T., Mokhtarzadeh, A., Brunetti, O., Silvestris, N., & Baradaran, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.676181 · Cited by 78
New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors
de Morais, A. L. G., Cerdá, S. S., & Miguel, M. J. D. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01218-y · Cited by 78
Karlsen, K. F., Tekle, C., Andersson, Y., Flatmark, K., Fodstad, Ø., & Nunes‐Xavier, C. E. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12599 · Cited by 77
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Wong, S. K., Nebhan, C. A., & Johnson, D. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786046 · Cited by 76
Zhu, X., Sun, L., Song, N., He, W., Xie, B., Hu, J., Zhang, J., Yang, J., Dai, J., Bian, D., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02696-4 · Cited by 76
Ortega, M. A., Boaru, D. L., León-Oliva, D. D., Fraile‐Μartinez, O., Montero, C. G., Rios, L., Garrido-Gil, M. J., Barrena-Blázquez, S., Minaya‐Bravo, A., Rios‐Parra, A., et al. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02463-3 · Cited by 76
Bharaj, P., Chahar, H. S., Alozie, O. K., Rodarte, L., Bansal, A., Goepfert, P., Dwivedi, A. K., Manjunath, N., & Shankar, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109103 · Cited by 75
HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT
Rodríguez-Barbosa, J.-I., Schneider, P., Weigert, A., Lee, K., Kim, T.-J., Pérez‐Simón, J. A., & del Rio, M. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0241-1 · Cited by 73
Yang, J., Dong, L., Yang, S., Han, X., Han, Y., Jiang, S., Yao, J., Zhang, Z., Zhang, S., Liu, P., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.028 · Cited by 72
Kang, S.-H., Keam, B., Ahn, Y.-O., Park, H.-R., Kim, M., Kim, T. M., Kim, D.-W., & Heo, D. S. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1515057 · Cited by 72
Buss, C. G., & Bhatia, S. N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2001569117 · Cited by 70
Wu, B., Zhong, C., Lang, Q., Liang, Z., Zhang, Y., Zhao, X., Yu, Y., Zhang, H., Xu, F., & Tian, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02068-5 · Cited by 70
Saha, A., & Chatterjee, S. K. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02355.x · Cited by 68
Rivas, J. R., Liu, Y., Alhakeem, S. S., Eckenrode, J. M., Martí, F., Collard, J. P., Zhang, Y., Shaaban, K. A., Muthusamy, N., Hildebrandt, G. C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01217-1 · Cited by 68
Wang, B., Liu, J., Yin, H., Deng, Y., Li, J., & Jiang, Y. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.868155 · Cited by 68
Yim, J., Koh, J., Kim, S., Song, S. G., Ahn, H. K., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.033 · Cited by 67
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
Zhao, X., Bao, Y., Meng, B., Xu, Z., Li, S., Wang, X., Hou, R., Ma, W., Liu, D., Zheng, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.920021 · Cited by 67
Clingan, P. R., Ladwa, R., Brungs, D., Harris, D. L., McGrath, M. L., Arnold, S., Coward, J. I. G., Fourie, S., Kurochkin, A., Malan, D. R., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007637 · Cited by 67
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66
Chen, W., Liu, P., Wang, Y., Nie, W., Li, Z., Xu, W., Li, F., Zhou, Z., Zhao, M., & Liu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076965 · Cited by 64
Ando, K., Hamada, K., Watanabe, M., Ohkuma, R., Shida, M., Onoue, R., Kubota, Y., Matsui, H., Ishiguro, T., Hirasawa, Y., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13716 · Cited by 64
Roehle, K., Li, Q., Ventre, K. S., Heid, D., Ali, L. R., Lenehan, P. J., Heckler, M., Crowley, S. J., Stump, C. T., Ro, G., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf5058 · Cited by 64
Jaeger, M., Pinelli, M., Borghi, M., Costantini, C., Dindo, M., van Emst, L., Puccetti, M., Pariano, M., Ricaño-Ponce, I., Büll, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3558 · Cited by 62
Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation
Lozano, T., Villanueva, L., Durántez, M., Gorraiz, M., Ruiz, M., Belsúe, V., Riezu-Boj, J., Hervás-Stubbs, S., Oyarzábal, J., Bandukwala, H. S., et al. (2015) · Journal of Immunology · doi:10.4049/jimmunol.1402997 · Cited by 60
Kawazu, M., Ueno, T., Saeki, K., Sax, N., Togashi, Y., Kanaseki, T., Chida, K., Kishigami, F., Sato, K., Kojima, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.10.010 · Cited by 59
Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 59
Mouse PVRIG Has CD8+ T Cell–Specific Coinhibitory Functions and Dampens Antitumor Immunity
Murter, B., Pan, X., Ophir, E., Alteber, Z., Azulay, M., Sen, R., Levy, O., Dassa, L., Vaknin, I., Kfir, T. F., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0460 · Cited by 58
Schwartz, S., Patel, N., Longmire, T. A., Jayaraman, P., Jiang, X., Lu, H., Baker, L. M., Velez, J., Ramesh, R., Wavreille, A., et al. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac019 · Cited by 58
Catenacci, D. V. T., Kang, Y., Yoon, H. H., Shim, B. Y., Kim, S. T., Oh, D., Spira, A. I., Ulahannan, S., Avery, E. J., Boland, P. M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100563 · Cited by 57
Kwatra, V., Karanth, N. V., Priyadarshana, K., & Charakidis, M. (2017) · Journal of Medical Case Reports · doi:10.1186/s13256-017-1229-z · Cited by 56
Current Status on Therapeutic Molecules Targeting Siglec Receptors
Lenza, M. P., Atxabal, U., Oyenarte, I., Jiménez‐Barbero, J., & Ereño‐Orbea, J. (2020) · Cells · doi:10.3390/cells9122691 · Cited by 56
CD96 expression determines the inflammatory potential of IL-9–producing Th9 cells
Stanko, K., Iwert, C., Appelt, C., Vogt, K., Schumann, J., Strunk, F. J., Ahrlich, S., Schlickeiser, S., Romagnani, C., Jürchott, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708329115 · Cited by 55
Choi, J. H., Medikonda, R. T., Saleh, L., Kim, T., Pant, A., Srivastava, S., Kim, Y., Jackson, C., Tong, L., Routkevitch, D., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1956142 · Cited by 55
Lian, B., Li, Z., Wu, N., Li, M., Chen, X., Zheng, H. Y., Gao, M., Wang, D., Sheng, X., Tian, H., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.793 · Cited by 55
Transmembrane Signaling by G Protein–Coupled Receptors
Jacob, C., & Bunnett, N. W. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50006-4 · Cited by 54
Integrative Analysis of Siglec-15 mRNA in Human Cancers Based on Data Mining
Li, Q., Huang, Z., Chen, Y.-B., Yao, H., Ke, Z., He, X., Qiu, M.-J., Wang, M., Xiong, Z.-F., & Yang, S. (2020) · Journal of Cancer · doi:10.7150/jca.38747 · Cited by 54
BTLA biology in cancer: from bench discoveries to clinical potentials
Andrzejczak, A., & Karabon, L. (2024) · Biomarker Research · doi:10.1186/s40364-024-00556-2 · Cited by 54
Tim-3 and Tim-4 as the potential targets for antitumor therapy
Cheng, L., & Ruan, Z. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1056953 · Cited by 53
Recent Advances in Cancer Therapeutics
Chessum, N. E. A., Jones, K., Pasqua, E., & Tucker, M. (2015) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2014.11.002 · Cited by 53
Nectin‐2 in ovarian cancer: How is it expressed and what might be its functional role?
Bekes, I., Löb, S., Holzheu, I., Janni, W., Baumann, L., Wöckel, A., & Wulff, C. (2019) · Cancer Science · doi:10.1111/cas.13992 · Cited by 53
Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity
Yang, H., Wang, X., Zhang, Y., Liu, H., Liao, J., Shao, K., Chu, Y., & Liu, G. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24426 · Cited by 52
Long, G. V., Hodi, F. S., Lipson, E. J., Schadendorf, D., Ascierto, P. A., Matamala, L., Salman, P., Gutiérrez, E. C., Rutkowski, P. L., Gogas, H. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.36_suppl.360385 · Cited by 52
Floudas, C. S., Brar, G. S., Mabry‐Hrones, D., Duffy, A. G., Wood, B. J., Levy, E. B., Krishnasamy, V. P., Fioravanti, S., Bonilla, C. M., Walker, M., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.06.004 · Cited by 51
Shimizu, T., Nakajima, T. E., Yamamoto, N., Yonemori, K., Koyama, T., Kondo, S., Sunakawa, Y., Izawa, N., Horie, Y., Xiang, S., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01287-7 · Cited by 51
Iadonato, S. P., Ovechkina, Y. Y., Lustig, K., Cross, J., Eyde, N., Frazier, E., Kabi, N., Katz, C., Lance, R., Peckham, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1311658 · Cited by 51
BTLA and HVEM Cross Talk Regulates Inhibition and Costimulation
Gavrieli, M., Šedý, J. R., Nelson, C. A., & MURPHY, K. M. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)92004-5 · Cited by 50
Role of co-stimulation in CD8+ T cell activation
Pardigon, N. (1998) · International Immunology · doi:10.1093/intimm/10.5.619 · Cited by 50
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer
Ducoin, K., Oger, R., Mutala, L. B., Deleine, C., Jouand, N., Desfrançois, J., Podevin, J., Duchalais, E., Cruard, J., Benlalam, H., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2046931 · Cited by 50
Scirocchi, F., Strigari, L., Filippo, A. D., Napoletano, C., Pace, A., Rahimi, H., Botticelli, A., Rughetti, A., Nuti, M., & Zizzari, I. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214496 · Cited by 50
Hashimoto, A., Gao, C., Mastio, J., Kossenkov, A. V., Abrams, S. I., Purandare, A. V., Desilva, H., Wee, S., Hunt, J., Jure‐Kunkel, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1229 · Cited by 49
Zhen, G., Dan, Y., Wang, R., Dou, C., Guo, Q., Zarr, M., Liu, L. N., Chen, L., Deng, R., Li, Y., et al. (2021) · Bone Research · doi:10.1038/s41413-021-00161-1 · Cited by 47
Fine-tuning of T cell responses during infection
Dorhoi, A., & Kaufmann, S. H. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.07.004 · Cited by 47
CTLA‐4 co‐receptor impacts on the function of Treg and CD8+ T‐cell subsets
Rudd, C. E. (2009) · European Journal of Immunology · doi:10.1002/eji.200939261 · Cited by 47
Radhakrishnan, V. S., Banavali, S. D., Gupta, S., Kumar, A. A., Deshmukh, C. D., Nag, S., Beniwal, S. K., Gopichand, M., Naik, R., Lakshmaiah, K., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz253.035 · Cited by 47
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
Battin, C., Leitner, J. M., Waidhofer‐Söllner, P., Grabmeier‐Pfistershammer, K., Olive, D., & Steinberger, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956694 · Cited by 47
Shan, L., Yang, Z., Li, D., Miao, X., Yang, L., Zou, Q., & Yuan, Y. (2015) · Disease Markers · doi:10.1155/2015/379568 · Cited by 45
Zaghi, E., Calvi, M., Marcenaro, E., Mavilio, D., & di Vito, C. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0718-300r · Cited by 44
Prenzler, S., Rudrawar, S., Waespy, M., Kelm, S., Anoopkumar‐Dukie, S., & Haselhorst, T. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1931171 · Cited by 44
Siglec-15: An Attractive Immunotherapy Target
(2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2019-136 · Cited by 44
Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board
Mingari, M. C., Pietra, G., & Moretta, L. (2019) · Trends in Immunology · doi:10.1016/j.it.2018.12.009 · Cited by 43
Lian, B., Si, L., H., Z., Sheng, X., Kong, Y., Wang, X., Tian, H., Li, K., Mao, L., Bai, X. L., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.002 · Cited by 43
The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
Kozłowski, M., Borzyszkowska, D., & Cymbaluk‐Płoska, A. (2022) · Biomedicines · doi:10.3390/biomedicines10112826 · Cited by 43
Soluble PD-L1 as a Predictive Biomarker in Lung Cancer: A Systematic Review and Meta-Analysis
Cheng, Y., Wang, C., Wang, Y., & Li, D. (2021) · Future Oncology · doi:10.2217/fon-2021-0641 · Cited by 41
Cohen, R. B., Bauman, J. R., Salas, S., Colevas, A. D., Even, C., Cupissol, D., Posner, M. R., Lefebvre, G., Saâda-Bouzid, E., Bernadach, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.6516 · Cited by 40
The role of neoantigens in tumor immunotherapy
Shang, S., Zhao, Y., Qian, K., Qin, Y., Zhang, X., Li, T., Shan, L., Wei, M., Xi, J., & Tang, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113118 · Cited by 39
LAG‐3 : recent developments in combinational therapies in cancer
Chavanton, A., Mialhe, F., Abrey, J., Garcia, A. B., & Garrido, C. (2024) · Cancer Science · doi:10.1111/cas.16205 · Cited by 38
Garapati, P. V., & Lefranc, M. (2007) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2007.01.008 · Cited by 37
Molecular characterization of HLA class II binding to the LAG‐3 T cell co‐inhibitory receptor
MacLachlan, B. J., Mason, G. H., Greenshields‐Watson, A., Triebel, F., Gallimore, A., Cole, D. K., & Godkin, A. J. (2020) · European Journal of Immunology · doi:10.1002/eji.202048753 · Cited by 37
B7-H3 in Medulloblastoma-Derived Exosomes; A Novel Tumorigenic Role
Purvis, I. J., Velpula, K. K., Guda, M. R., Nguyen, D., Tsung, A. J., & Asuthkar, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197050 · Cited by 37
Immunotherapy in patients with autoimmune disease
Rakshit, S., & Molina, J. R. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-2019-cptn-10 · Cited by 36
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade
Song, E., & Chow, R. D.-W. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.013 · Cited by 35
PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia
Li, J., Whelan, S., Kotturi, M. F., Meyran, D., D’Souza, C., Hansen, K., Liang, S. C., Hunter, J., Trapani, J. A., & Neeson, P. J. (2020) · Haematologica · doi:10.3324/haematol.2020.258574 · Cited by 34
Dong, M., Chen, J., Deng, Y., Zhang, D., Dong, L., & Sun, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701736 · Cited by 34
Naing, A., Infante, J. R., Goel, S., Burris, H. A., Black, C., Marshall, S. A., Achour, I., Barbee, S. D., May, R., Morehouse, C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0665-2 · Cited by 33
Xie, C., You, X., Zhang, H., Li, J., Wang, L., Liu, Y., Wang, Z., Yao, R., Tong, T., Li, M., et al. (2023) · Advanced Science · doi:10.1002/advs.202300418 · Cited by 33
Advancement of anti‐LAG ‐3 in cancer therapy
Li, Y., Ju, M., Miao, Y., Zhao, L., Xing, L., & Wei, M. (2023) · The FASEB Journal · doi:10.1096/fj.202301018r · Cited by 33
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
Catalano, M., Shabani, S., Venturini, J., Ottanelli, C., Voltolini, L., & Roviello, G. (2022) · Cancers · doi:10.3390/cancers14246145 · Cited by 32
Mohsenzadegan, M., Baghshahi, P. B., Nowroozi, M. R., Amini, E., Kourosh‐Arami, M., Momeni, S. A., Bokaie, S., & Sharifi, L. (2021) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530321666210310142141 · Cited by 31
Xu, R., Mai, H., Chen, Q., Chen, D., Hu, C., Yang, K., Wen, J., Li, J., Shi, Y., Jin, F., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.lba2 · Cited by 31
TIGIT blockade enhances NK cell activity against autologous HIV‐1‐infected CD4+ T cells
Holder, K. A., Burt, K., & Grant, M. D. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1348 · Cited by 31
Adenosine Receptors as Novel Targets for the Treatment of Various Cancers
Gorain, B., Choudhury, H., Yee, G. S., & Bhattamisra, S. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190716102037 · Cited by 30
Ginderachter, J. A. V., Liu, Y., Geldhof, A. B., Brijs, L., Thielemans, K., Baetselier, P. D., & Raes, G. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000815)87:4<539::aid-ijc13>3.0.co;2-e · Cited by 30
Li, M., Qiao, D., Pu, J., Wang, W., Zhu, W., & Liu, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.7953 · Cited by 29
Fröhlich, A., Niebel, D., Fietz, S., EGGER, E. K., Buchner, A., Sirokay, J. D., & Landsberg, J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02487-x · Cited by 29
Chen, H., Zha, J., Tang, R., & Chen, G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110418 · Cited by 29
Conserved and variable natural killer cell receptors: diverse approaches to viral infections
Bastidas-Legarda, L. Y., & Khakoo, S. I. (2018) · Immunology · doi:10.1111/imm.13039 · Cited by 28
Yoon, S. J., Lee, C. B., Chae, S. U., Jo, S. J., & Bae, S. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136932 · Cited by 28
Mehlman, C., Kamga, P. T., Costantini, A., Julié, C., Duménil, C., Dumoulin, J., Ouaknine, J., Giraud, V., Chinet, T., Emile, J., et al. (2021) · Cancers · doi:10.3390/cancers13051107 · Cited by 27
Zenke, S., Sica, M. P., Steinberg, F., Braun, J. M., Zink, A., Gavrilov, A., Hilger, A., Arra, A., Brunner-Weinzierl, M. C., Elling, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34156-1 · Cited by 27
Bissonnette, R. P., Cesario, R. M., Goodenow, B., Shojaei, F., & Gillings, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08702-x · Cited by 24
MAP kinase p38 and its relation to T cell anergy and suppressor function of regulatory T cells
Adler, H. S., & Steinbrink, K. (2008) · Cell Cycle · doi:10.4161/cc.7.2.5312 · Cited by 24
Novel CD47: SIRPα Dependent Mechanism for the Activation of STAT3 in Antigen-Presenting Cell
Natan, T., Gur‐Wahnon, D., Adi, B.-Y., & Rachmilewitz, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075595 · Cited by 23
Structures of Immune Checkpoints: An Overview on the CD28-B7 Family
Liu, W., & Zang, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9367-9_3 · Cited by 23
Rao, S., Capdevila, J., Gilbert, D. C., Kim, S. C. H., Dahan, L., Kayyal, T., Fakih, M., Demols, A., Jensen, L. H., Spindler, K.-L. G., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2272 · Cited by 23
Khan, S. A., Pruitt, S. L., Xuan, L., Makris, U. E., & Gerber, D. E. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.024 · Cited by 22
Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers
Fujimura, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23074044 · Cited by 21
Role of PKCs and NF-κB activation in myocardial inflammation: Enemy or ally?
Abe, J. (2007) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.07.002 · Cited by 19
McHale, D., Francisco-Anderson, L., Sandy, P., Shariffudin, S., Goldberg, M., Gardner, H., Abdou, M., Kashyap, S., Argueta, S., Parameswaran, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.407 · Cited by 18
Lim, W., Wang, H., Li, S.-H., Ngan, R. K. C., Dechaphunkul, A., Zhang, L., Yen, C. J., Chan, P. C., Chakrabandhu, S., Ma, B. B. Y., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct150 · Cited by 16
Voss, M. H., Azad, A. A., Hansen, A. R., Gray, J. E., Welsh, S. J., Song, X., Kuziora, M., Meinecke, L., Blando, J. M., Achour, I., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4115 · Cited by 16
Tawbi, H. A., Hodi, F. S., Lipson, E. J., Schadendorf, D., Ascierto, P. A., Matamala, L., Salman, P., Gutiérrez, E. C., Rutkowski, P. L., Gogas, H. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.9505 · Cited by 16
Zhang, W., Wang, R., Fang, H., Ma, X., Li, D., Liu, T., Chen, Z., Wang, K., Hao, S., Yu, Z., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.415 · Cited by 14
Huang, R. Y. ‐., Wang, Y., Jhatakia, A., Deng, A., Bee, C., Deshpande, S. V., Rangan, V. S., Bezman, N., Gudmundsson, O. S., & Chen, G. (2021) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.0c00399 · Cited by 13
Simian Immunodeficiency Virus Infection Modulates CD94 + (KLRD1 + ) NK Cells in Rhesus Macaques
Ram, D. R., Lucar, O., Hueber, B., & Reeves, R. K. (2019) · Journal of Virology · doi:10.1128/jvi.00731-19 · Cited by 12
Mi, Z., Zhang, Y., Feng, Z., Liu, J., Wu, J., Tan, H., Ma, X., Liu, Z., & Rong, P. (2022) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2022.2131354 · Cited by 10
Chiappori, A., Williams, C. C., Creelan, B., Tanvetyanon, T., Gray, J. E., Haura, E. B., Chen, D. T., Thapa, R., Beg, A. A., Boyle, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.747 · Cited by 10
Galot, R., Tourneau, C. L., Saâda-Bouzid, E., Daste, A., Even, C., Debruyne, P. R., Henry, S., Zanetta, S., Rutten, A., Licitra, L. F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz252.001 · Cited by 10
Entinostat Helps Thwart Immunotherapy Resistance
(2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2019-048 · Cited by 10
Cited by
The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances
Chen, H., Yang, H., Guo, L., & Sun, Q. (2025) · MedComm · doi:10.1002/mco2.70412 · Cited by 66
Li, J., Peng, J., Wang, J., & Chen, Z. (2025) · Med Research · doi:10.1002/mdr2.70022 · Cited by 62
Han, X., Zhang, J., Li, W., Huang, X., Wang, X., Wang, B., Gao, L., & Chen, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1512509 · Cited by 55
Roussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 34
Dendritic cell immunotherapy advances for solid tumors: Vaccination and modulation
Clayton, G., Toffoli, E. C., de Gruijl, T. D., & van Kooyk, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102412 · Cited by 30
Metadata
- Authors
- Arafat Hossain, M.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 143
- Issue
- Pt 2
- Pages
- 113365
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W4403679157
- Cited by
- 178
- References
- 626
- FWCI
- 27.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.